
    
      The study was conducted as an open label, balanced, randomized two-treatment, two-period,
      two-sequence, single-dose, crossover bioequivalence study comparing sumatriptan succinate
      tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
      manufactured by OHM Laboratories Inc. with IMITREXÂ® 100 mg tablets (containing sumatriptan
      succinate equivalent to 100 mg of sumatriptan) manufactured by GlaxoSmithKline Research
      Triangle Park NC 27709, Made in Canada in healthy, adult, male, human, subjects under fed
      conditions.

      Following an overnight fast of at least 10 hour, a single oral dose of sumatriptan succinate
      tablets 100 mg of either test or reference formulation was administered during each period of
      the study, along with 240 mL of drinking water at ambient temperature under supervision of
      trained study personnel 30 min after start of a high fat high calorie breakfast.

      Thirty-two 32 subjects were enrolled into the study. Twenty-four (24) subjects completed both
      the periods of the study.

      Pharmacokinetic and statistical analyses were performed on data from 24 subjects who
      completed both the periods of the study.
    
  